Comparative Pharmacology
Head-to-head clinical analysis: HETRAZAN versus VERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETRAZAN versus VERMOX.
HETRAZAN vs VERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
Binds to β-tubulin in parasitic cells, inhibiting microtubule polymerization, thereby impairing glucose uptake and causing energy depletion and parasite death.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
Mebendazole 100 mg orally twice daily for 3 days for pinworm, whipworm, hookworm, and roundworm infections. For pinworm, may repeat after 2 weeks. For hookworm and whipworm, may require longer courses.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
2-8 hours (terminal half-life, may be prolonged in hepatic impairment or obstruction)
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Fecal (90%) as unchanged drug and metabolites; renal (<10%)
Category C
Category C
Anthelmintic
Anthelmintic